Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Prestige Consumer HealthcarePBH -2.24%69 PB Ratio is 1.25 as of Aug. 20, 2026, which is 32% below its 10-year median of 1.83. GuruFocus rates PBH with a GF Score™ of 69/100 and a GF Value™ of $70.51 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 916 Drug Manufacturers companies, Prestige Consumer Healthcare ranks better than 67.9% on this metric.
Prestige Consumer Healthcare Inc stock PB Ratio (=1.28) is close to 5-year low of 1.17.
The historical rank and industry rank for Prestige Consumer Healthcare's PB Ratio or its related term are showing as below:
PBH'
s PB Ratio Range Over the Past 10 Years
Min: 1.14 Med: 1.83 Max: 3.81
Current: 1.25
During the past 13 years, Prestige Consumer Healthcare's highest PB Ratio was 3.81. The lowest was 1.14. And the median was 1.83.
PBH's PB Ratio is ranked better than 67.9% of 916
companies
in the Drug Manufacturers industry
Industry Median: 1.965
vs PBH: 1.25
During the past 12 months, Prestige Consumer Healthcare's average Book Value Per Share Growth Rate was 7.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 11.10% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 7.50% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 10.30% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Prestige Consumer Healthcare was 234.00% per year. The lowest was -36.20% per year. And the median was 12.40% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Prestige Consumer Healthcare PB Ratio Related Terms
Prestige Consumer Healthcare PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Prestige Consumer Healthcare's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prestige Consumer Healthcare PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Prestige Consumer Healthcare's PB Ratio distribution charts can be found below:
* The bar in red indicates where Prestige Consumer Healthcare's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Prestige Consumer Healthcare (PBH) has a PB Ratio of 1.25 as of Aug. 20, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Prestige Consumer Healthcare and its competitors. This is 32% below median its historical median of 1.83. Over the past decade, Prestige Consumer Healthcare's PB Ratio has ranged from 1.14 to 3.81. According to the industry distribution chart, Prestige Consumer Healthcare ranks #294 out of 916 companies in the Drug Manufacturers industry, placing it in the top 32.1%.
Is Prestige Consumer Healthcare's PB Ratio too high?
Prestige Consumer Healthcare's current PB Ratio of 1.25 is 32% below median its 10-year median of 1.83. Over the past 10 years, this metric has ranged from a low of 1.14 to a high of 3.81. The Drug Manufacturers industry median PB Ratio is 1.97. Prestige Consumer Healthcare's value of 1.25 is 36.4% below this industry median. Based on the distribution chart, Prestige Consumer Healthcare ranks #294 out of 916 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Prestige Consumer Healthcare has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Prestige Consumer Healthcare's PB Ratio compare to BCRX and AMLX?
According to the Drug Manufacturers industry distribution chart, Prestige Consumer Healthcare ranks #294 out of 916 companies for PB Ratio. This puts Prestige Consumer Healthcare in the upper half of its industry. The industry median PB Ratio is 1.97. Prestige Consumer Healthcare's value of 1.25 is 36.4% below this benchmark. Historically, Prestige Consumer Healthcare's own PB Ratio has ranged from 1.14 to 3.81 over the past decade. While the company's 10-year median is 1.83 vs. the industry median of 1.97, Prestige Consumer Healthcare has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.97, based on 916 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Prestige Consumer Healthcare's current PB Ratio of 1.25 is 36.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Prestige Consumer Healthcare and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prestige Consumer Healthcare's current PB Ratio is 1.25, which is 32% below median its own 10-year median of 1.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prestige Consumer Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Prestige Consumer Healthcare (PBH) is currently considered Modestly Undervalued. The stock's GF Value™ is $70.51, compared to a current price of $50.52 — trading 28.4% below its estimated fair value. The current PB Ratio is 1.25, which is 32% below median its 10-year median of 1.83 and 36.4% below the Drug Manufacturers industry median of 1.97. Prestige Consumer Healthcare's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Prestige Consumer Healthcare (PBH), the current PB Ratio is 1.25 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Prestige Consumer Healthcare (PBH) Overvalued in 2026?
Based on GuruFocus' analysis, Prestige Consumer Healthcare stock appears to be undervalued.
The current stock price of $50.52 is trading 28.4% below its estimated GF Value™ of $70.51.
GuruFocus considers Prestige Consumer Healthcare to be Modestly Undervalued.
Key valuation signals for PBH:
PB Ratio: 1.25 (32% below median its 10-year median of 1.83)
GF Value™: $70.51 vs. price of $50.52 (28.4% below fair value)
Industry Position: 36.4% below the Drug Manufacturers median (#294 of 916)
No single metric tells the full story. See the PBH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
69GF Score
Get the complete analysis for PBH
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PBH has been successfully added to your 
